GlassScriptPhysician profile
Kimberly A Bibb
NPI 1568495869
$994.80
in general payments reported to CMS, 2019-2025
15 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.45 · 2021: $227 · 2022: $107 · 2023: $56.21 · 2024: $217 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.49 | 2020-2025 | Wegovy, Saxenda, Rybelsus |
| Lilly USA, LLC | $63.13 | 2024-2025 | Mounjaro, Zepbound |
| Soleno Therapeutics, INC. | $62.47 | 2025 | Vykat Xr |
| Abbott Laboratories | $61.92 | 2023-2025 | Freestyle Libre 3 |
| Kvk-Tech, INC. | $54.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $43.52 | 2024 | |
| Inari Medical, INC. | $41.79 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $24.80 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $23.33 | 2022 | |
| Vivus LLC | $22.76 | 2021 | |
| Standard Bariatrics, INC. | $19.43 | 2022 | |
| Endo Pharmaceuticals INC. | $19.43 | 2021 | |
| Currax Pharmaceuticals LLC | $17.47 | 2023 | Contrave |
| Astrazeneca Pharmaceuticals LP | $15.09 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $14.76 | 2024 | Vaxneuvance, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Bibb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.